Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 5, 2007, Pages 987-993

  Janneh, Omar ^a,b   Jones, Elizabeth ^b   Chandler, Becky ^b   Owen, Andrew ^b   Khoo, Saye H ^b  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Antiretroviral transport; MRP1; MRP2; P gp

Indexed keywords

AMPRENAVIR; ATAZANAVIR; DIPYRIDAMOLE; FUROSEMIDE; GLYCOPROTEIN P; LOPINAVIR; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PROBENECID; RITONAVIR; TARIQUIDAR; VERLUKAST;

ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG DISTRIBUTION; DRUG POTENTIATION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, VIRAL; GENE EXPRESSION REGULATION; HIV-1; HUMANS; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PYRIMIDINONES; RNA, MESSENGER;

EID: 35448967118     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm353     Document Type: Article

References (38)

1. Choo EF, Leake B, Wandel C et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000; 28 655-60.
2. Paolucci S, Baldanti F, Campanini G et al. Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patents. J Med Virol 2001; 65: 207-17.
3. Zhang L, Ramratnam B, Tenner-Racz K et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 340: 1605-13.
4. Deeks SG, Volberding PA. HIV-1 protease inhibitors. AIDS Clin Rev 1997; 98: 145-85.
5. Taylor S, Back DJ, Drake SM. Antiretroviral drug concentrations in semen of HIV-infected men: Differential penetration of indinavir, ritonavir and saquinavir. J Antimicrob Chemother 2001; 48: 351-4.
6. Sadler BM, Piliero PJ, Preston SL et al. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, coadministration to healthy volunteers. AIDS 2001; 15: 1009-18.
7. Koks CH, Crommentuyn KM, Hoetelmans RM et al. The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals. Br J Clin Pharmacol 2001; 51: 631-5.
8. Khaliq Y, Gallicano K, Tisdale C et al. Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers. Br J Clin Pharmacol 2001; 51: 591-600.
9. Kim AE, Dintaman JM, Waddell DS et al. Saquinavir, an HIV protease inhibitor is transported by P-glycoprotein. J Pharmacol Exp Ther 1998; 286: 11439-45.
10. Lee CG, Gottesman MM, Cardarelli CO et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug - transporter. Biochemistry 1998; 37: 3594-601.
11. Jorres K, Bray PG, Khoo SH et al. P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: Potential for accelerated viral drug resistance? AIDS 2001; 15: 1353-8.
12. Huisman MT, Smit JW, Crommentuyn KM et al. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 2002; 16: 2295-301.
13. Janneh O, Owen A, Chandler B et al. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS 2005; 19 2097-102.
14. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000; 14: 237-42.
15. Clayette P, Jorajuria S, Dormont D. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000; 14: 235-6.
16. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998; 35: 275-91.
17. Fauci A, Bartlett JG, Goosby E. Early treatment of HIV-1 infection. Lancet 1998; 352: 1935.
18. Mistry P, Stewart AJ, Dangerfield W et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 2001; 61: 749-58.
19. Robey RW, Steadman K, Polgar O et al. Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res 2004; 64 1242-6.
20. Letschert K, Faulstich H, Keller D et al. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci 2006; 91: 140-9.
21. Verstuyft C, Strabach S, El-Morabet H et al. Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin Pharmacol Ther 2003; 73: 51-60.
22. Dickinson L, Robinson L, Tjia J et al. Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 829: 82-90.
23. Owen A, Chandler B, Back DJ et al. Expression of pregnane-X-raceptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. Antivir Ther 2004; 9: 819-21.
24. Meaden ER, Hoggard PG, Maher B et al. Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17: 1329-32.
25. Cooray HC, Blackmore CG, Maskell L et al. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 2002; 13: 2059-63.
26. Gutmann H, Fricker G, Drewe J et al. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 1999; 56: 383-9.
27. Perloff MD, von Moltke LL, Fahey JM et al. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS 2000; 14: 1287-9.
28. Ford J, Meaden ER, Hoggard PG et al. Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression. J Antimicrob Chemother 2003; 52: 354-8.
29. Gupta A, Zhang Y, Unadkat JD et al. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther 2004; 310: 334-41.
30. Su Y, Zhang X, Sinko PJ. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of saquinavir in Hep G2 cells. Mol Pharmacol 2004; 1: 49-56.
31. van der Sandt IC, Vos CM, Nabulsi L et al. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood - brain barrier. AIDS 2001; 15: 483-91.
32. van Heeswijk RP, Veldkamp AI, Hoetelmans RM et al. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS 1999; 13: F95-9.
33. Piscitelli SC, Vogel S, Figg WD et al. Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus. Pharmacotherapy 1998; 18: 1212-6.
34. Washington CB, Duran GE, Man MC et al. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19: 203-9.
35. Hoggard PG, Back DJ. Intracellular pharmacology of nucleoside analogues and protease inhibitors: Role of transporter molecules. Curr Opin Infect Dis 2002; 15: 3-8.
36. Khoo SH, Hoggard PG, Williams I et al. Intracellular accumulation of human immunodeficiency virus protease inhibitors. Antimicrob Agents Chemother 2002; 46: 3228-35.
37. Woodahl EL, Yang Z, Bui T et al. MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS 2005; 19: 1617-25.
38. Agarwal S, Pal D, Mitra AK. Both P-gp and MRP2 mediate transport of lopinavir, a protease inhibitor. Int J Pharm 2007; 339: 139-47.